

**DIL Limited**

Audited financial results for year ended March 31, 2012.

Sr.No.	Particulars	Statement of Audited Financial Results for the Year Ended March 31, 2012.						Consolidated							
		Standalone			Consolidated			Unaudited			Audited				
		Quarter ended		Audited Year Ended	Quarter ended		Audited Year Ended	Quarter ended		Audited Year Ended	Quarter ended		Audited Year Ended		
		Audited	Unaudited	March 31, 2012	March 31, 2011	March 31, 2012	March 31, 2011	Audited	Unaudited	March 31, 2012	March 31, 2011	March 31, 2012	March 31, 2011		
1	<b>Income from operations</b>														
	a) Net sales/Income from operations	517.10	382.22	1,809.26	1,411.77	3,496.30	2,209.92	3,518.42	2,209.92	11,799.31	7,677.32				
	b) Other operating income (refer note 4)	8.20	157.60	31.93	224.99	22.09	108.67	131.97	108.67	387.06	194.75				
	Total income from operations (net)	525.30	539.82	1,841.19	1,636.76	3,518.39	2,318.59	3,650.39	2,318.59	12,186.37	7,872.07				
2	<b>Expenses</b>														
	a) Cost of material consumed	-	-	45.06	-	828.42	602.84	1,140.51	602.84	3,849.64	2,082.53				
	b) Cost of production of movie	-	-	-	-	-	-	-	-	45.06	-				
	c) Purchase of stock in trade	-	-	(45.06)	-	57.93	5.53	(79.88)	5.53	104.03	5.53				
	d) Change in inventories of finished goods, work in process and stock in trade	-	-	-	-	285.12	(162.01)		(162.01)	(206.44)	(255.06)				
	e) Employee benefits expense	68.86	93.07	331.39	305.41	411.99	361.68	526.00	361.68	1,820.38	1,395.19				
	f) Depreciation and amortisation expense	88.05	25.80	170.98	116.58	273.88	112.07	197.15	112.07	776.07	415.03				
	g) Processing charges	-	-	-	-	125.87	128.64	93.24	128.64	464.26	318.70				
	h) Legal & professional expenses	29.28	21.81	104.83	349.24	122.17	196.62	65.76	196.62	362.02	579.48				
	i) Repairs & maintenance	34.49	19.54	101.52	127.36	62.94	37.68	46.30	37.68	205.75	170.62				
	j) Other expenditure	53.38	52.97	206.42	195.23	556.79	412.73	611.74	412.73	2,169.60	1,417.13				
	Total expenses (a to j)	274.06	313.40	915.14	1,093.82	2,725.11	1,695.78	2,600.82	1,695.78	9,590.37	6,129.15				
3	Profit from operations before other income, finance costs & exceptional items (1-2)	251.24	226.42	926.05	542.94	793.28	622.81	1,049.57	622.81	2,596.00	1,742.92				
4	Other income	-	0.01	11.40	30.44	16.89	9.09	13.54	9.09	58.78	41.26				
5	Profit from ordinary activities before finance cost & exceptional items (3+4)	251.24	226.43	937.45	573.38	810.17	631.90	1,063.11	631.90	2,654.78	1,784.18				
6	Finance costs	2.03	2.14	7.45	6.96	134.95	38.15	117.00	38.15	387.59	127.79				
7	Profit from ordinary activities after finance cost but before exceptional items (5-6)	249.21	224.29	930.00	566.42	675.22	593.75	946.11	593.75	2,267.19	1,656.39				
8	Exceptional items	-	-	-	-	-	-	-	-	-	-				
	a) Earn out income (refer note 2)	-	-	-	413.55	-	-	-	-	-	413.55				
	b) Profit on sale of investment in associate/subsidiary (refer note 3)	-	1,743.59	910.81	1,743.59	-	-	1,069.25	1,564.67	1,069.25	1,564.67				
9	Profit/(Loss) from ordinary activities before tax (7+8)	249.21	1,967.88	1,840.81	2,723.56	675.22	2,158.42	2,015.36	2,158.42	3,336.44	3,634.61				
10	Tax expense	44.18	243.29	372.70	546.72	122.24	351.72	351.72	351.72	640.18	834.92				
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	205.03	1,552.42	1,468.11	2,176.84	552.98	1,607.90	1,663.64	1,607.90	2,696.26	2,799.69				
12	Provision for tax in respect of earlier years written back (net)	-	-	-	-	(0.35)	(0.29)	-	(0.29)	(0.35)	(0.37)				
13	Net Profit/(Loss) for the period/year (11+12)	205.03	1,552.42	1,468.11	2,176.84	552.63	1,607.61	1,663.64	1,607.61	2,695.91	2,799.32				
14	Share of profit/(loss) of associates	-	-	(41.49)	(34.33)	(41.49)	(34.33)	(46.96)	(34.33)	(172.65)	(142.89)				
15	Minority interest	-	-	(96.71)	(153.69)	(96.71)	(107.02)	(153.69)	(107.02)	(297.53)	(123.58)				
16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates	205.03	1,552.42	1,468.11	2,176.84	414.43	1,466.26	1,462.99	1,466.26	2,225.73	2,552.85				
17	Paid-up equity share capital (Face value Rs 10/- per share)	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32				
18	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year.	-	-	9,275.68	8,607.13	-	-	-	-	12,704.28	11,320.18				
19 i)	Basic and diluted earning per share of ₹10/- each before extraordinary items	8.94	67.70	64.02	94.93	18.07	63.94	63.80	63.94	97.06	110.45				
19 ii)	Basic and diluted earning per share of ₹10/- each after extraordinary items	8.94	67.70	64.02	94.93	18.07	63.94	63.80	63.94	97.06	110.45				

© For quarter only and not annualised except for year end results

Sr.No.	Particulars	Standalone				Consolidated			
		Quarter ended		Audited Year Ended		Quarter ended		Unaudited	
		Audited March 31, 2012	Unaudited December 31, 2011	March 31, 2011	March 31, 2012	Audited March 31, 2012	Unaudited December 31, 2011	March 31, 2011	March 31, 2012
A.	PARTICULARS OF SHAREHOLDING	1	Public shareholding	843,834	926,905	843,834	926,905	843,834	926,905
			- Number of shares	36.80%	40.42%	36.80%	40.42%	36.80%	40.42%
2	Promoters and promoter group shareholding		a) Pledged/ Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
			- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
			b) Non-encumbered	1,449,364	1,366,293	1,449,364	1,366,293	1,449,364	1,366,293
			- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
			- Percentage of shares (as a % of the total share capital of the Company)	63.20%	59.58%	63.20%	59.58%	63.20%	59.58%

B	PARTICULARS	3 MONTHS ENDED MARCH 31, 2012				
		Fending at beginning of the quarter	Received during the quarter	Disposed during the quarter	Remaining unresolved at the end of the quarter	Nil
	INVESTOR COMPLAINTS	Nil	5	5	5	Nil

Segment	Particulars	Standalone				Consolidated			
		Quarter ended		Audited Year Ended		Quarter ended		Unaudited	
		Audited March 31, 2012	Unaudited December 31, 2011	March 31, 2011	March 31, 2012	Audited March 31, 2012	Unaudited December 31, 2011	March 31, 2011	March 31, 2012
Segment revenue		329.72	323.99	300.22	1,267.66	3,027.98	3,189.22	1,971.82	6,550.65
	- Bulk drugs/chemicals	194.96	173.32	89.15	571.33	1,949.96	1,733.32	89.15	1,285.66
Less: Inter-segment revenue		0.62	0.33	150.45	2.20	0.27	(0.21)	151.79	1.31
	Total	525.30	497.64	539.82	1,841.19	3,558.39	3,650.39	2,318.59	8,200.75
Net sales/income from operation		525.30	497.64	539.82	1,841.19	3,558.39	3,650.39	2,318.59	8,200.75
	Less: Inter-segment revenue					39.04	40.43	197.39	328.68
Segment results {profit/(loss) before interest and tax}		216.05	284.75	289.69	1,023.83	542.84	768.62	560.68	1,397.55
	- Property	193.01	167.89	(98.66)	559.55	219.68	288.44	291.81	1,038.40
Less: Interest expense		(22.25)	(15.56)	(7.54)	(73.56)	(22.57)	(15.95)	(7.54)	(59.55)
	- Entertainment	(135.57)	(152.63)	42.93	(583.77)	(136.15)	(153.50)	42.17	(75.89)
Add: Unallocable income		251.24	284.45	226.42	926.05	796.81	1,055.50	967.38	2,123.55
	Exceptional items	251.24	284.45	226.42	926.05	796.81	1,055.50	967.38	2,123.55
Profit before tax		2.03	1.98	2.14	7.45	134.95	117.00	38.15	387.59
	a) Profit on sale of investment in associate/subsidiary (refer note 3)		3.37	0.01	11.40	16.89	13.54	9.09	58.78
Capital employed (segment assets less segment liabilities)		249.21	1,196.65	1,967.88	1,840.81	6,775.22	2,015.36	2,158.42	3,336.44
	- Bulk Drugs/chemicals	973.97	584.20	665.16	973.97	8,747.28	7,831.06	6,106.77	8,747.28
Total capital employed		8,668.27	9,043.76	7,776.50	8,668.27	6,629.67	7,046.63	5,793.59	6,629.67
	- Treasury	(248.52)	316.20	250.99	(248.52)	(3,598.53)	(2,371.22)	(1,227.63)	(3,598.53)

Statement of Assets and Liabilities PARTICULARS		₹. in Lakhs			
		Standalone	Consolidation		
		As at current year end March 31, 2012	As at previous year end March 31, 2011	As at current year end March 31, 2012	As at previous year end March 31, 2011
<b>A</b>	<b>EQUITY AND LIABILITIES</b>				
1	<b>Shareholders' funds</b>	229.32	229.32	229.32	229.32
	(a) Share capital	9,275.68	8,607.13	12,704.28	11,320.18
	(b) Reserves and surplus	9,505.00	8,836.45	12,933.60	11,549.50
	<b>Sub-total - Shareholder's funds</b>		1,974.30		1,676.77
2	<b>Minority interest</b>				
3	<b>Non-current liabilities</b>	58.92	56.50	1,964.92	1,078.21
	(a) Long-term borrowings	17.53	25.33	24.60	34.81
	(b) Deferred tax liabilities (net)	77.27	92.12	77.27	137.43
	(c) Other long term liabilities	22.06	1.42	174.77	150.96
	(d) Long-term provisions	175.78	175.37	2,241.56	1,401.41
4	<b>Current liabilities</b>			1,259.27	555.94
	(a) Short-term borrowings	298.08	29.12	1,642.93	824.56
	(b) Trade payables	603.58	562.46	1,074.58	812.16
	(c) Other current liabilities	439.64	298.57	504.46	313.62
	(d) Short-term provisions	1,341.30	890.15	4,481.24	2,506.28
	<b>Sub-total - Current liabilities</b>	11,022.08	9,901.97	21,630.70	17,133.96
	<b>TOTAL EQUITY AND LIABILITIES</b>				
<b>B</b>	<b>ASSETS</b>				
1	<b>Non-current assets</b>	1,691.36	1,298.34	8,150.87	5,601.80
	(a) Fixed assets			413.33	413.33
	(b) Goodwill on consolidation			968.49	484.99
	(c) Non-current investments	2,844.76	2,302.78	514.20	602.98
	(d) Long term loans and advances	133.66	82.33	8.43	2.14
	(e) Other non-current assets			10,055.32	7,105.24
	<b>Sub-total - Non-current assets</b>	4,669.78	3,683.45		
2	<b>Current assets</b>	805.37	3,628.45	805.37	3,628.45
	(a) Current investments	45.06		2,152.54	1,062.47
	(b) Inventories	25.88	124.56	2,337.12	1,685.37
	(c) Trade receivables	4,340.52	1,314.96	5,009.25	2,406.81
	(d) Cash and cash equivalents	893.21	1,054.29	1,031.67	1,151.40
	(e) Short-term loans and advances	242.26	96.26	239.43	93.63
	(f) Other current assets	6,352.30	6,218.52	11,575.38	10,028.13
	<b>Sub-total - Current assets</b>	11,022.08	9,901.97	21,630.70	17,133.96
3	<b>Miscellaneous expenditure</b>				0.59
	<b>TOTAL ASSETS</b>				

**NOTES:**

- 1 DIL Limited ('the Company') is in the business of renting properties, motion film production and distribution and treasury operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in manufacturing of bulk drugs, development of discoidal electrical motor technology and providing services of sporting and health awareness/education activities.  
The above audited financial results are presented on a standalone basis as well as on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture.
- 2 The audited consolidated financial results include the results of an associate and joint venture on the basis of unaudited financial statements prepared by the management.
- 3 As per the terms of Share Purchase and Shareholder's Agreement (Agreements) executed by the Company on August 31, 2009 for transferring 70% of paid up equity share capital of Evotec (India) Pvt. Ltd. to Evotec AG, in addition to sales consideration of Rs. 1,117.71 Lakhs, the Company was entitled to earnout based on earnout revenue during the twelve months period ended 31st August 2010. Accordingly, during the previous year the Company has accounted and received an earnout revenue of Rs. 413.55 Lakhs.
- 4 During the current year, the Company has completed transaction based on Share Purchase Agreement dated September 28, 2011 executed with Evotec AG and transferred 1,09,26,000 fully paid up equity shares of Rs. 2/- each i.e. 30% of the paid up equity share capital of Evotec (India) Pvt. Ltd. for a total consideration of Rs. 1,129.33 Lakhs resulting in a gain of Rs. 910.81 Lakhs in standalone financial results and Rs. 1,069.25 Lakhs in consolidated financial results and disclosed under exceptional item.
- 5 During the previous year, the Company had entered into Technology Sale and Transfer agreement and transferred the bulk drug technology to Fermenta Biotech Limited for a consideration of Rs. 150 Lakhs.
- 6 During the year ended March 31, 2009, Company's subsidiary, Fermenta Biotech Limited (FBL), had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I. Biotech Private Limited (G.I.). Simultaneously Company has also entered into a share transfer agreement with Ronator Investments Limited (RI), a company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I. in four installments to be completed by February 10, 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the earlier year FBL sold 3750 shares for consideration of USD 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been further extended to December 31, 2012.
- 7 Based on the audited financial statements of the Company for the year ended March 31, 2011, the Company sought clarification from the Reserve Bank of India (RBI) confirming that the Company fulfills the Principal Business Criteria as laid down by RBI to be a Non-Banking Financial Company. RBI has advised the Company to stop Non-Banking Financial Institution (NBFI) activities and submit a time-bound action plan to reduce financial assets supported by a Board Resolution. Accordingly, the Board of Directors of the Company in its meeting has decided that the Company does not intend to undertake any NBFI activities. Based on submission by the Company, RBI has given time upto March 2013 to the Company for not obtaining certificate of registration by reducing the investments in Financial Assets. The Company has taken corrective action which are reflected in the financial statement for the year ended March 31, 2012 for not to be a NBFC Company.
- 8 The Company has obtained a permission from Thane Municipal Corporation (TMC) for redevelopment of part of its property situated at DIL Complex Thane (W) 400610 by giving a conditional undertaking that entire existing civil structure will be demolished on completion of new building. Accordingly the Company has amortised the net cost of the Thane building as on October 1, 2011 over revised remaining estimated useful life of 39 months beginning October 1, 2011. Consequently depreciation charge for the current year in respect of Thane building is ₹ 85.56 lakhs. Had the Company continued the earlier useful life of 58 years as applicable to the building the depreciation charge would have been lower by ₹. 56.43 Lakhs and the profit before tax would have been higher by the same amount.
- 9 The figures for the quarter ended March 31, 2012 and March 31, 2011 are the balancing figures between the audited figures in respect of full financial year and the year to date figures upto the third quarter.
- 10 The Board of Directors at their meeting held on May 29, 2012 have proposed a final dividend of 150% (₹. 15/- per share) for the financial year 2011-12.
- 11 Till the year ended March 31, 2011, the company was using pre-revised Schedule VI to the Companies Act 1956, for preparation and presentation of its financial statements. During the year ended 31 March 2012, the revised Schedule VI notified under the Companies Act 1956, has become applicable to the company. The company has reclassified previous year figures to conform to this year's classification.
- 12 The above audited annual results have been taken on record by the Board of Directors in its meeting held on May 29, 2012.

Thane  
May 29, 2012

For DIL Limited

  
K. Krishna Datta  
Managing Director



DIL Limited

DIL Complex, Ghodbunder Road, Thane(W)- 400 610, INDIA.

Audited financial results for year ended March 31, 2012.

Tel. : +91-22-6798 0888

: +91-22-6798 0800

Fax : +91-22-6798 0999

Email : contact@dil.net

www.dil.net

(₹. in Lakhs)

Sr.No.	Particulars	Consolidated				
		Quarter ended			Audited Year Ended	
		Audited	Unaudited		March 31, 2012 (Note 1)	March 31, 2011 (Note 1)
		March 31, 2012 (Note 1 & 8)	December 31, 2011 (Note 1)	March 31, 2011 (Note 1)		
1	a) Net sales/ Income from operations	3,496.30	3,518.42	2,209.92	11,799.31	7,677.32
	b) Other operating income (refer note 4)	22.09	131.97	108.67	387.06	194.75
	Total income from operations (net)	3,518.39	3,650.39	2,318.59	12,186.37	7,872.07
2	Expenditure					
	a) Cost of material consumed	828.42	1,140.51	602.84	3,849.64	2,082.53
	b) Cost of production of motion film	-	-	-	45.06	-
	c) Purchase of stock in trade	57.93	-	5.53	104.03	5.53
	d) Change in inventories of finished goods, work in process and stock in trade	285.12	(79.88)	(162.01)	(206.44)	(255.06)
	e) Employees cost	411.99	526.00	361.68	1,820.38	1,395.19
	f) Depreciation/ Impairment	273.88	197.15	112.07	776.07	415.03
	g) Processing charges	125.87	93.24	128.64	464.26	318.70
	h) Legal & professional expenses	122.17	65.76	196.62	362.02	579.48
	i) Repairs & maintenance	62.94	46.30	37.68	205.75	170.62
	j) Other expenditure	556.79	611.74	412.73	2,169.60	1,417.13
	Total expenditure (a to i)	2,725.11	2,690.82	1,695.78	9,590.37	6,129.15
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	793.28	1,049.57	622.81	2,596.00	1,742.92
4	Other income	16.89	13.54	9.09	58.78	41.26
5	Profit before Interest & Exceptional Items (3+4)	810.17	1,063.11	631.90	2,654.78	1,784.18
6	Interest	134.95	117.00	38.15	387.59	127.79
7	Profit after interest but before Exceptional Items (5-6)	675.22	946.11	593.75	2,267.19	1,656.39
8	Exceptional items					
	a) Earn out income (refer note 2)	-	-	-	-	413.55
	b) Profit on sale of investment in associate/subsidiary (refer note 3)	-	1,069.25	1,564.67	1,069.25	1,564.67
9	Profit/ (Loss) from Ordinary Activities before tax (7+8)	675.22	2,015.36	2,158.42	3,336.44	3,634.61
10	Tax expense	122.24	351.72	550.52	640.18	834.92
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	552.98	1,663.64	1,607.90	2,696.26	2,799.69
12	Provision for tax in respect of earlier years written back	(0.35)	-	(0.29)	(0.35)	(0.37)
13	Net Profit/(Loss) for the period/year (11+12)	552.63	1,663.64	1,607.61	2,695.91	2,799.32
14	Share of Profit / (Loss) of Associate Companies	(41.49)	(46.96)	(34.33)	(172.65)	(142.89)
15	Share of minority interest	(96.71)	(153.69)	(107.02)	(297.53)	(123.58)
16	Net Profit/ (Loss) after minority interest and share in associates	414.43	1,462.99	1,466.26	2,225.73	2,532.85
17	Paid-up equity share capital (Face value Rs 10/- per share)	229.32	229.32	229.32	229.32	229.32
18	Reserves excluding revaluation reserves				12,704.28	11,320.18
19	i) Basic and diluted earning per share of ₹10/- each before extraordinary items	18.07	63.80	63.94	97.06	110.45
	ii) Basic and diluted earning per share of ₹10/- each after extraordinary items	18.07	63.80	63.94	97.06	110.45

@ For quarter only and not annualised except for year end results.

PART II						
SELECT INFORMATION FOR THE YEAR ENDED MARCH 31, 2012.						
Sr.No.	Particulars	Consolidated				
		Quarter ended			Audited Year Ended	
		Audited	Unaudited		March 31, 2012 (Note 1)	March 31, 2011 (Note 1)
		March 31, 2012 (Note 1 & 8)	December 31, 2011 (Note 1)	March 31, 2011 (Note 1)		
20	Public shareholding					
	- Number of shares	843,834	855,046	926,905	843,834	926,905
	- Percentage of shareholding	36.80%	37.29%	40.42%	36.80%	40.42%
21	Promoters and promoter group shareholding					
	a) Pledged/ Encumbered					
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the Company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of shares	1,449,364	1,438,152	1,366,293	1,449,364	1,366,293
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the Company)	63.20%	62.71%	59.58%	63.20%	59.58%

3 MONTHS ENDED MARCH 31, 2012				
PARTICULARS	Pending at beginning of the quarter	Received during the quarter	Disposed of during the quarter	Remaining unresolved at the end of the quarter
B INVESTOR COMPLAINTS	Nil	5	5	Nil

2

Particulars	-Consolidated				
	Quarter ended			Audited Year Ended	
	Audited	Unaudited		2012	2011
	March 31, 2012 (Note 1 & 8)	December 31, 2011 (Note 1)	March 31, 2011 (Note 1)	March 31, 2012 (Note 1)	March 31, 2011 (Note 1)
Segment revenue					
- Bulk drugs/chemicals	3,027.98	3,189.22	1,971.82	10,487.31	6,550.65
- Property	334.22	328.49	303.22	1,285.66	1,230.14
- Treasury	194.96	173.32	89.15	571.33	265.86
- Entertainment	-	-	-	-	-
- Unallocable	0.27	(0.21)	151.79	1.31	154.10
Total	3,557.43	3,690.82	2,515.98	12,345.61	8,200.75
Less : Inter-segment revenue	39.04	40.43	197.39	159.24	328.68
Net sales/income from operation	3,518.39	3,650.39	2,318.59	12,186.37	7,872.07
Segment results {profit/(loss) before interest and tax}					
- Bulk drugs/chemicals	542.84	768.62	560.68	1,681.37	1,397.55
- Property	219.68	288.44	291.81	1,038.40	1,008.00
- Treasury	193.01	167.89	80.26	559.55	250.62
- Entertainment	(22.57)	(15.95)	(7.54)	(75.89)	(64.41)
- Unallocable	(136.15)	(153.50)	42.17	(587.51)	(468.21)
Total	796.81	1,055.50	967.38	2,615.92	2,123.55
Less: Inter-segment results	3.53	5.93	344.57	19.92	380.63
Less : Interest expense	793.28	1,049.57	622.81	2,596.00	1,742.92
Add: Unallocable income	134.95	117.00	38.15	387.59	127.79
Exceptional items	16.89	13.54	9.09	58.78	41.26
a) Earn out income (refer note .2)	-	-	-	-	413.55
b) Profit on sale of investment in associate/subsidiary (refer note 3)	-	1,069.25	1,564.67	1,069.25	1,564.67
Profit before tax	675.22	2,015.36	2,158.42	3,336.44	3,634.61
Capital employed (Segment assets Less Segment liabilities)					
- Bulk drugs/chemicals	8,747.28	7,831.06	6,106.77	8,747.28	6,106.77
- Property	1,041.23	653.38	728.56	1,041.23	728.56
- Treasury	6,629.67	7,046.63	5,793.59	6,629.67	5,793.59
- Entertainment	113.95	158.36	148.21	113.95	148.21
- Unallocable	(3,598.53)	(2,371.22)	(1,227.63)	(3,598.53)	(1,227.63)
Total Capital employed	12,933.60	13,318.21	11,549.50	12,933.60	11,549.50

Consolidated Statement of Assets and Liabilities		₹. in Lakhs	
PARTICULARS		Consolidation	
		As at current year end March 31, 2012	As at previous year end March 31, 2011
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' Funds		
(a)	Share Capital	229.32	229.32
(b)	Reserves and Surplus	12,704.28	11,320.18
	Sub-total - shareholder' funds	12,933.60	11,549.50
2	Minority interest	1,974.30	1,676.77
3	Non-Current Liabilities		
(a)	Long-term borrowings	1,964.92	1,078.21
(b)	Deferred tax liabilities (Net)	24.60	34.81
(c)	Other Long term liabilities	77.27	137.43
(d)	Long-term provisions	174.77	150.96
	Sub-total - Non-Current Liabilities	2,241.56	1,401.41
4	Current Liabilities		
(a)	Short-term borrowings	1,259.27	555.94
(b)	Trade payables	1,642.93	824.56
(c)	Other current liabilities	1,074.58	812.16
(d)	Short-term provisions	504.46	313.62
	Sub-total - Current Liabilities	4,481.24	2,506.28
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>21,630.70</b>	<b>17,133.96</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current assets		
(a)	Fixed assets	8,150.87	5,601.80
(b)	Goodwill on consolidation	413.33	413.33
(c)	Non-current investments	968.49	484.99
(d)	Long term loans and advances	514.20	602.98
(e)	Other non-current assets	8.43	2.14
	Sub-total - Non-Current Assets	10,055.32	7,105.24
2	Current assets		
(a)	Current investments	805.37	3,628.45
(b)	Inventories	2,152.54	1,062.47
(c)	Trade receivables	2,337.12	1,685.37
(d)	Cash and cash equivalents	5,009.25	2,406.81
(e)	Short-term loans and advances	1,031.67	1,151.40
(f)	Other current assets	239.43	93.63
	Sub-total - Current Assets	11,575.38	10,028.13
	Miscellaneous Expenditure		0.59
	<b>TOTAL ASSETS</b>	<b>21,630.70</b>	<b>17,133.96</b>

NOTES:


- 1 DIL Limited ('the Company') is in the business of renting properties, motion film production and distribution and treasury operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in manufacturing of bulk drugs, development of discoidal electrical motor technology and providing services of sporting and health awareness/education activities.  
The above audited quarterly financial results are presented on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture.  
The audited consolidated financial results includes the results of a associate and joint venture on the basis of unaudited financial statements prepared by the management.
- 2 As per the terms of Share Purchase and Shareholder's Agreement (Agreements) executed by the Company on August 31, 2009 for transferring 70% of paid up equity share capital of Evotec (India) Pvt. Ltd. to Evotec AG, in addition to sales consideration of Rs. 1,117.71 Lakhs, the Company was entitled to earnout based on earnout revenue during the twelve months period ended 31st August 2010. Accordingly, during the previous year the Company has accounted and received an earnout revenue of Rs. 413.55 Lakhs.
- 3 During the current quarter, the Company has completed transaction based on Share Purchase Agreement dated September 28, 2011 executed with Evotec AG and transferred 1,09,26,000 fully paid equity shares of Rs. 2/- each i.e. 30% of the paid up equity share capital of Evotec (India) Pvt. Ltd. for a total consideration of Rs. 1,129.33 Lakhs resulting in a gain of Rs. 1,069.25 Lakhs in consolidated financial results and disclosed under exceptional item.
- 4 During the previous year, the Company had entered into Technology Sale and Transfer agreement and transferred the bulk drug technology to Fermenta Biotech Limited for a consideration of Rs. 150 Lakhs.
- 5 During the year ended March 31, 2009, Company's subsidiary, Fermenta Biotech Limited (FBL), had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I Biotech Private Limited (G.I.). Simultaneously Company has also entered into a share transfer agreement with Ronator Investments Limited (RI), a company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I in four installments to be completed by February 10, 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the earlier year FBL sold 3750 shares for consideration of USD 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been further extended to December 31, 2012.
- 6 Based on the audited financial statements of the Company for the year ended March 31, 2011, the Company sought clarification from the Reserve Bank of India (RBI) confirming that the Company fulfills the Principal Business Criteria as laid down by RBI to be a Non-Banking Financial Company. RBI has advised the Company to stop Non-Banking Financial Institution (NBFI) activities and submit a time-bound action plan to reduce financial assets supported by a Board Resolution. Accordingly, the Board of Directors of the Company in its meeting has decided that the Company does not intend to undertake any NBFI activities. Based on submission by the Company, RBI has given time upto March 2013 to the Company for not obtaining certificate of registration by reducing the investments in Financial Assets. The Company has taken corrective action which are reflected in the financial statement for the year ended March 31, 2012 for not to be a NBFC Company.
- 7 The Company has obtained a permission from Thane Municipal Corporation (TMC) for redevelopment of part of its property situated at DIL Complex Thane (W) 400610 by giving a conditional undertaking that entire existing civil structure will be demolished on completion of new building. Accordingly the Company has amortised the net cost of the Thane building as on October 1, 2011 over revised remaining estimated useful life of 39 months beginning October 1, 2011. Consequently depreciation charge for the current year in respect of Thane building is ₹ 85.56 lakhs. Had the Company continued the earlier useful life of 58 years as applicable to the building the depreciation charge would have been lower by ₹. 56.43 Lakhs and the profit before tax would have been higher by the same amount.
- 8 The figures for the quarter ended March 31, 2012 and March 31, 2011 are the balancing figures between the audited figures in respect of full financial year and the year to date figures upto the third quarter.
- 9 The Board of Directors at their meeting held on May 29, 2012 have proposed a final dividend of 150% (₹ 15/- per share) for the financial year 2011-12.
- 10 Till the year ended March 31, 2011, the company was using pre-revised Schedule VI to the Companies Act 1956, for preparation and presentation of its financial statements. During the year ended 31 March 2012, the revised Schedule VI notified under the Companies Act 1956, has become applicable to the company. The company has reclassified previous year figures to conform to this year's classification.
- 11 In accordance with clause 41, consolidated financial results have been published. However, standalone financial results are available on the Company's website www.dil.net and BSE website. Additional information on standalone basis are as follows

Particulars	Quarter ended			Audited Year Ended	
	March 31,	December 31,	March 31,	March 31,	March 31,
	2012	2011	2011	2012	2011
Revenue	525.30	1,411.82	2,283.42	2,763.40	3,824.34
Profit before tax	249.21	1,196.65	1,967.88	1,840.81	2,723.56
Profit after tax	205.03	953.36	1,552.42	1,468.11	2,176.84

- 12 The above audited annual results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on May 29, 2012.

Thane  
May 29, 2012

For DIL Limited

  
Krishna Datla  
Managing Director

